INNOVATION
from cell to society

Fifth Annual Research Conference
February 7 - 9, 2010
Fairmont Le Château Frontenac, Québec City, QC
2010 Conference Planning Committee

Claude Roy
Gastroenterologist and Professor Emeritus, Hôpital Ste-Justine; Board of Directors, AllerGen NCE Inc.; Chair, Annual Research Conference Committee, Montreal, QC

Judah Denburg
AllerGen Scientific Director & CEO, McMaster University, Hamilton, ON

Allan Becker
Professor, Department of Paediatrics, University of Manitoba; AllerGen Programme C, Co-Lead, Winnipeg, MB (HQP)

Dean Befus
Professor, Department of Medicine, University of Alberta; AllerGen Programme B, Co-Lead, Edmonton, AB

Mark Bisby
Consultant, AllerGen Board of Directors, Ottawa, ON

Richard Warrington
President, Canadian Society of Allergy and Clinical Immunology, Ottawa, ON

Zave Chad
Associate Professor, University of Ottawa; Canadian Paediatric Society; AllerGen Board of Directors, Ottawa, ON

Claire Martin
Consultant, AllerGen Board of Directors, Quebec City, QC

Diana Royce
AllerGen Managing Director & COO, Hamilton, ON (HQP)

Kelly McNagny
Professor, Department of Medical Genetics, University of British Columbia; AllerGen Researcher, Vancouver, BC (Chair, HQP)

Oxana Latycheva
Vice President, Programming, Asthma Society of Canada; AllerGen Education and Training Opportunities Advisory Committee (AETOCA) member, Toronto, ON (HQP)

Jennifer Protudjer
Manitoba Institute of Child Health; President AllerGen Students and New Professional Network (ASNPN); AllerGen Board of Directors, Winnipeg, MB (HQP)

Danuta Radzioch
Professor Centre for the Study of Host Resistance Montreal General Hospital; AETOCA Member, Montreal, QC (HQP)

* HQP - These members also were part of the Highly Qualified Personnel (HQP) Conference Planning Sub-Committee

Committee Support

Melissa Shuker
Program Coordinator, (HQP)

Jessie Ielati
Senior Communications Officer

Mark Mitchell
Manager, Research and Partnerships

Liz Dzaman
Executive Assistant and Corporate Secretary

AllerGen is supported by the Government of Canada through the Networks of Centres of Excellence program.
AllerGen est appuyé par le gouvernement du Canada dans le cadre du programme des Réseaux de centres d’excellence.
Contents

Conference Information ............................................................ 2
Networks of Centres of Excellence (NCE) Program ....................... 2
Welcome from the Board Chair and Scientific Director ................ 3
Keynote Speakers .................................................................. 4
Conference Programme .......................................................... 5
Fairmont Le Château Frontenac: Floor plan. .............................. 5
Featured Speakers .................................................................. 10
About AllerGen ....................................................................... 15
AllerGen’s Sixth Annual Research Conference, 2011 ................. 16
Sponsors ............................................................................. 17

Proud Gold Sponsor of the
AllerGen NCE Inc.
Fifth Annual Research Conference

© 2016 King Pharmaceuticals, Inc. | www.kingpharm.ca | 877-374-7361
Conference Information

The registration desk is located in the foyer of the Salle de bal on the second floor of the Fairmont Le Château Frontenac.
The registration desk will be staffed at the following times:
Saturday, February 6 ................. 3:00 pm to 6:00 pm
Sunday, February 7 .................. 9:00 am to 5:00 pm
Monday, February 8 .................. 8:30 am to 7:00 pm
Tuesday, February 9 ................. 8:30 am to Noon

Admission to conference events is by CONFERENCE NAME BADGE ONLY. Registrations are non-transferable and sharing of registration is not permitted.

Full registration includes:
- Sunday Welcome Reception, all breakfasts, breaks, lunches and Monday evening Reception and Gala Dinner
- All sessions
- Conference handouts

Networks of Centres of Excellence (NCE) Program

Who we are:
We are a joint program of the Natural Sciences and Engineering Research Council of Canada, the Social Sciences and Humanities Research Council of Canada, the Canadian Institutes of Health Research and Industry Canada. Launched in 1989 to manage the original Network of Centres of Excellence (NCE), today the NCE Secretariat runs four national initiatives:
- Networks of Centres of Excellence (NCE)
- Centres of Excellence for Commercialization and Research (CECRs)
- Business-Led Networks of Centres of Excellence (BL-NCEs)
- Industrial Research and Development Internship program (IRDI)

Our mission:
We mobilize research and commercialization to build a healthier, more advanced, more competitive and more prosperous Canada.

How we do it:
The four NCE programs bring together partners from the academic, industry, public and non-profit sectors to conduct leading edge research and knowledge transfer activities in areas of strategic growth and opportunity for Canada.

Programme des Réseaux de centres d’excellence (RCE)

Le programme :
Le Programme des Réseaux de centres d’excellence (RCE) est un programme conjoint du Conseil de recherches en sciences naturelles et en génie du Canada, du Conseil de recherches en sciences humaines du Canada, des Instituts de recherche en santé du Canada et d’Industrie Canada. Le Programme des RCE a été lancé en 1989 dans le but de gérer les premier réseaux. à l’heure actuelle, le Secrétariat des RCE exécute les quatre programmes nationaux suivants :
- les Réseaux de centres d’excellence (RCE);
- les Centres d’excellence en commercialisation et en recherche (CECR);
- les Réseaux de centres d’excellence dirigés par les entreprises (RCE-E);
- les stages en R et D industrielle (SRDI).

Notre mission :
Nous mobilisons le talent en recherche et en commercialisation afin d’édifier un Canada plus sain, plus avancé, plus concurrentiel et plus prospère.

Notre façon de faire :
Les quatre programmes des RCE réunissent des partenaires du milieu universitaire, des secteurs privé et public et du secteur sans but lucratif afin de mener de la recherche de pointe et des activités de transfert de connaissances dans des domaines d’importance stratégique en croissance et fertiles de possibilités au Canada.
Welcome from the Board Chair and Scientific Director

On behalf of the AllerGen Board of Directors, Research Leaders, Administrative Centre and our generous conference sponsors, we welcome you to our Fifth Annual Research Conference, Innovation from Cell to Society®, at the picturesque Fairmont Le Château Frontenac, in Québec City.

Since 2005, AllerGen has fostered a national network of allergy and immune disease experts and partner organizations with international collaborators in eight countries. This premier conference offers an exclusive opportunity to network with AllerGen’s 134 researchers and clinician-scientists, 386 research trainees and new professionals, international experts from a wide range of disciplines, as well as representatives from the Network’s industry, government, health care, academic and not-for-profit partner organizations.

This year’s conference showcases the results of AllerGen’s nationally networked research across the full range of Network investment. The aim is to accelerate social and economic impact by applying these results to real world problems and challenges faced by partner organizations, sectors of the Canadian economy and society.

We are delighted to feature several internationally recognized keynote speakers at this year’s event, including Dr. Stephen Holgate, Clinical Professor of Immunopharmacology, Southampton General Hospital, United Kingdom; Dr. Neal Cohen, Professor of Anesthesia & Perioperative Care & Medicine and Vice-Dean of the School of Medicine, University of California, San Francisco and Dr. Alan James, Clinical Associate Professor, Medicine and Pharmacology at the University of Western Australia.

In addition to our keynote speakers, many of AllerGen’s outstanding researchers will be showcasing their research results, which would not have been possible without the support of the Network. Conference attendees will have the opportunity to experience first hand the research excellence of AllerGen’s research trainees who will be displaying and presenting 50 scientific posters as part of the Annual Student Poster Competition. AllerGen’s investment in the future of this specialty is vital in order to reduce the burden of allergic disease and ultimately increase the quality of health and productivity of Canadians.

We hope that you enjoy this conference and are confident that it will be a worthwhile learning and networking opportunity that will enable innovation in the fields of allergic and related immune disease.

Mr. Graham W.S. Scott, C.M., Q.C
Chair, AllerGen Board of Directors
AllerGen NCE Inc.

Dr. Judah Denburg, MD, FRCP(C)
Scientific Director and CEO
AllerGen NCE Inc.
Keynote Speakers

Stephen Holgate  Applying basic science to the clinical interface in asthma and allied disorders has been the guiding principle of Stephen Holgate’s career. His research interests have been focused on the cellular and molecular mechanisms of asthma that has involved use of epidemiological, clinical and genetic approaches. He has published over 850 papers in the peer reviewed literature.

He is currently Clinical Professor of Immunopharmacology, Southampton General Hospital, United Kingdom; Chairman of the Science Council’s Science in Health Group; member of the Royal Commission on Environmental Pollution; Chairman of the UK MRC Physiological Systems and Clinical Sciences Board and advises government on issues relating to air pollution and translational medicine.

Neal Cohen  is Professor of Anesthesia and Medicine and Vice Dean for the School of Medicine, University of California, San Francisco (UCSF). He also serves as the Medical Director of the International Service.

Dr. Cohen is responsible for oversight and approval of all academic and clinical affiliations between the School of Medicine, other academic and clinical institutions as well as industry, both nationally and internationally. He recently chaired the committee that developed the policy on Industry Relations and serves as chair for the task force that oversees the policy.

Dr. Cohen was recently awarded the Lifetime Achievement Award from the American Society of Critical Care Anesthesiologists. Dr. Cohen has authored numerous articles and presented lectures on a wide array of topics related to the care of critically ill patients, practice management and industry relations and its impact on innovations in health care, compliance and regulatory affairs.

Alan James  trained in respiratory medicine in Western Australia prior to taking up a position as a Canadian Research Fellow in Vancouver to study airway mechanics in asthma, the subject of his MD (PhD). Clinical Associate Professor Dr. James is a consultant respiratory physician at Sir Charles Gairdner Hospital and at Hollywood Private Hospital.

His research involves: 1) the investigation of airway narrowing in asthma and COPD, currently focusing on the stereological measurement of hyperplasia and hypertrophy of airway smooth muscle and the use of bronchial biopsy to study airway remodelling; 2) the investigation of genetic and environmental risk factors for respiratory disease in populations including the Busselton Health Studies and the characterisation of respiratory disease in remote indigenous communities.

As a representative of the Busselton Health Studies he is a member of AllerGen NCE Inc. He runs a research laboratory within the West Australian Sleep Disorders Research Institute and currently holds adjunct appointments for teaching and research at the University of Western Australia and Notre Dame University in Perth. He has published over 100 journal articles, book chapters and editorials.
Sunday, February 7, 2010

4:30 - 5:30 pm   Opening Ceremonies   Sale de bal

Welcome and Introductions

Mr. Graham W.S. Scott  
Chair, Board of Directors, AllerGen NCE Inc. and CEO, Graham Scott Strategies Inc.

Dr. Judah Denburg  
Scientific Director and CEO, AllerGen NCE Inc.

Welcome Messages

Dr. Suzanne Fortier  
President, NSERC and Chair, NCE Steering Committee

Mr. Jean-Claude Gavrel  
Vice-President, Networks of Centres of Excellence

Dr. Michael Kramer  
Scientific Director, CIHR Institute of Human Development, Child and Youth Health

Dr. Marc Ouellette  
Scientific Director, CIHR Institute of Infection and Immunity

Ms. Ainsley Chapman  
Director, The National Lung Health Framework

Dr. Louis-Philippe Boulet  
AllerGen Investigator, Laval University

5:30 - 7:00 pm   Opening Keynote Speaker

New Horizons in Allergy and Lung Health Research

Dr. Stephen T. Holgate  
Clinical Professor of Immunopharmacology, Southampton General Hospital, United Kingdom

7:00 – 8:00 pm   Welcome Reception for all Conference Delegates   Frontenac & Petit

8:00 – 10:00 pm   AllerGen Students and New Professionals   Bellevue

Network-Hosted Pub Night for all Conference Delegates
# Monday, February 8, 2010

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 - 8:50 am</td>
<td>Breakfast Buffet</td>
<td>Frontenac &amp; Petit</td>
</tr>
<tr>
<td>8:00 am - 5:00 pm</td>
<td>AllerGen Trainee Poster Viewing</td>
<td>Salle de bal Foyer</td>
</tr>
<tr>
<td>8:50 - 9:00 am</td>
<td>Welcome and Overview of Day Two Programme</td>
<td>Salle de bal</td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Claude Roy</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gastroenterologist and Professor Emeritus, Hôpital Ste-Justine,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Board of Directors, AllerGen NCE Inc. &amp; Chair, Annual Research Conference Committee</td>
<td></td>
</tr>
<tr>
<td>9:00 - 10:00 am</td>
<td>Keynote Speaker</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Open Innovation Networks Between Academic and Industry: An Imperative</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>for Breakthrough Therapies</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Neal H. Cohen</strong></td>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td></td>
<td><strong>Respondent</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Catherine Tribouley</strong></td>
<td>Merck Research Laboratories, Rahway, New Jersey</td>
</tr>
<tr>
<td>10:00 - 10:30 am</td>
<td>Break</td>
<td>Verchères</td>
</tr>
<tr>
<td>10:30 - 11:30 am</td>
<td>AllerGen Research Presentations</td>
<td>Salle de bal</td>
</tr>
<tr>
<td></td>
<td><strong>Public Health, Ethics, Policy and Society:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Improving the Quality of Life of Individuals with Anaphylaxis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session Sponsor:</strong></td>
<td><strong>Ava Armstrong</strong>, Director, Marketing</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong></td>
<td><strong>Dr. Allan Becker</strong></td>
</tr>
<tr>
<td></td>
<td><strong>AllerGen Public Health, Ethics, Policy and Society Research Programme Co-Leader</strong></td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:50 am</td>
<td>Surveying Canadians to assess the prevalence of common food allergies and attitudes towards food labeling and risk (SCAAALAR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Ann Clarke</strong></td>
<td>McGill University</td>
</tr>
<tr>
<td>10:50 - 11:10 am</td>
<td>Evaluation of the implementation and effectiveness of statutory and regulatory school-based policies for anaphylaxis risk reduction</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Lisa Cicutto</strong></td>
<td>University of Toronto</td>
</tr>
<tr>
<td>11:10 – 11:30 am</td>
<td>Roundtable Discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Allan Becker</strong>, Chair</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Samuel Godefroy</strong></td>
<td>Director General, Food Directorate, Health Canada</td>
</tr>
<tr>
<td></td>
<td><strong>Ms. Laurie Harada</strong></td>
<td>Executive Director, Anaphylaxis Canada</td>
</tr>
<tr>
<td></td>
<td><strong>Ms. Sara Shannon</strong></td>
<td>Anaphylaxis Safety and Awareness Advocate</td>
</tr>
<tr>
<td>11:30 am - 1:00 pm</td>
<td>Food Labeling and Risk Management</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:50 am</td>
<td><strong>Psycho-social Impacts of Anaphylaxis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Susan Elliott</strong></td>
<td>McMaster University</td>
</tr>
<tr>
<td>11:50 - 12:10 pm</td>
<td><strong>Predicting Peanut Allergy</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Susan Waserman</strong></td>
<td>McMaster University</td>
</tr>
<tr>
<td>12:10 - 12:30 pm</td>
<td><strong>E-Learning: Online course for schools</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Anthony Levinson</strong></td>
<td>McMaster University</td>
</tr>
</tbody>
</table>
12:30 - 1:00 pm   Roundtable Discussion  **Dr. Allan Becker**, Chair

- **Dr. Samuel Godefroy**  
  Director General, Food Directorate, Health Canada
- **Mr. Michael Hauptman**  
  Senior Education Manager at Alberta Education
- **Ms. Laurie Harada**  
  Executive Director, Anaphylaxis Canada
- **Ms. Sara Shannon**  
  Anaphylaxis Safety and Awareness Advocate

1:00 - 1:30 pm   Buffet Lunch  Frontenac & Petit

1:30 - 2:30 pm   AllerGen International Partnerships Initiatives Update

  **Moderator:** **Dr. Judah Denburg**  
  Scientific Director & CEO, AllerGen, NCE Inc

  Update on AllerGen collaborations with:
  - The Karolinska Institutet, Sweden  
    **Dr. Sven-Erik Dahlén**  
    Professor, Director of the Center for Allergy Research, Karolinska Institutet
  - St. John's Research Institute, Bangalore, India  
    **Dr. Krishnamachari Srinivasan**  
    Vice Dean, St. John’s Research Institute
  - The Global Alliance against Respiratory Diseases (GARD) - The Respiratory Global Research and Training (GReAT) Network  
    **Dr. Teresa To**  
    AllerGen Investigator, University of Toronto and The Hospital for Sick Children

2:30 - 3:00 pm   Trainee Poster Award Oral Presentation Competition  Salle de bal

  **Moderator:** **Dr. Chris Mody**  
  Chair, Advanced Education and Training Opportunities Advisory Committee (AETOAC)

  Gene-Environment Interactions

3:00 - 3:30 pm   Trainee Poster Award Oral Presentation Competition  Salle de bal

  Diagnostics & Therapeutics

3:30 - 3:45 pm   Break  Verchères

3:45 - 4:15 pm   Trainee Poster Award Oral Presentation Competition  Salle de bal

  Public Health, Ethics, Policy & Society

4:15 - 5:15 pm   The Biology of Food Allergies

  **Moderator:** **Dr. Paul O’Byrne**  
  AllerGen Diagnostics and Therapeutics Research Programme Co-Leader

  CanGoFar Team progress and accomplishments to date

  - **Dr. Jean Marshall**  
    Team Leader and AllerGen Investigator, Dalhousie University
  - **Dr. Manel Jordana**  
    AllerGen Investigator, McMaster University
  - **Dr. Jeremy Scott**  
    Assistant Professor, University of Toronto

5:15 pm   Adjournment

6:30 - 7:30 pm   AllerGen Trainee Poster Reception  Salle de bal

7:30 - 9:30 pm   Conference Gala Banquet & Trainee Awards  Salle de bal

*Innovation from cell to society*
## Tuesday, February 9, 2010

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 - 8:30 am</td>
<td>Breakfast Buffet</td>
<td>Frontenac &amp; Petit</td>
</tr>
<tr>
<td>8:30 - 8:35 am</td>
<td>Overview of Day Three Programme</td>
<td>Salle de bal</td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Diana Royce</strong>&lt;br&gt;Managing Director and COO, AllerGen NCE Inc.</td>
<td></td>
</tr>
<tr>
<td>8:35 - 9:30 am</td>
<td>Keynote Speaker&lt;br&gt;&lt;br&gt;<strong>Dissecting Asthma Sub-Phenotypes</strong>&lt;br&gt;<strong>Dr. Alan James</strong>, Associate Professor, Respiratory Medicine, University of Western Australia</td>
<td></td>
</tr>
<tr>
<td>9:30 – 10:30 am</td>
<td>Gene-Environment Interactions&lt;br&gt;<strong>Moderator:</strong> Dr. Jeff Brook&lt;br&gt;AllerGen Gene-Environment Interactions Programme Co-Leader</td>
<td></td>
</tr>
<tr>
<td>9:30 - 10:10 am</td>
<td><em>Land use regression models for assessment of long-term NO2 exposure:</em>&lt;br&gt;<strong>I. Model Development</strong>&lt;br&gt;<strong>Dr. Ryan Allen</strong>&lt;br&gt;AllerGen Investigator, Simon Fraser University</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Land use regression models for assessment of long-term NO2 exposure:</em>&lt;br&gt;<strong>II. Application to Epidemiologic Analyses</strong>&lt;br&gt;<strong>Dr. Chris Carlsten</strong>&lt;br&gt;AllerGen Investigator, University of British Columbia</td>
<td></td>
</tr>
<tr>
<td>10:10 - 10:30 am</td>
<td><em>Environmental assessment of home environment in mini-CHILD participants</em>&lt;br&gt;<strong>Dr. Tim Takaro</strong>&lt;br&gt;AllerGen Investigator, Simon Fraser University</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00 am</td>
<td>Break</td>
<td>Verchères</td>
</tr>
<tr>
<td>11:00 - 12:00 pm</td>
<td>Allergy Related Gene-Environment Interactions&lt;br&gt;<strong>Moderator:</strong> Dr. Denise Daley&lt;br&gt;AllerGen Gene-Environment Interactions Program Investigator</td>
<td>Salle de bal</td>
</tr>
<tr>
<td>11:00 - 11:20 am</td>
<td>Update on AllerGen’s role in the international GABRIEL collaboration&lt;br&gt;<strong>Dr. Andrew Sandford</strong>&lt;br&gt;AllerGen Investigator, University of British Columbia</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:40 am</td>
<td><em>Development and implementation of GENAPHA - an allergen-gene environment database resource</em>&lt;br&gt;<strong>Dr. Denise Daley</strong>&lt;br&gt;AllerGen Investigator, University of British Columbia</td>
<td></td>
</tr>
<tr>
<td>11:40 - 12:00 pm</td>
<td><em>An Overview of Asthma Genetics in French Canadian Population</em>&lt;br&gt;<strong>Dr. Catherine Laprise</strong>&lt;br&gt;AllerGen Investigator, University of Québec, Chicoutimi</td>
<td></td>
</tr>
<tr>
<td>12:00 - 1:00 pm</td>
<td>Lunch sponsored by McMaster University</td>
<td>Frontenac &amp; Petit</td>
</tr>
</tbody>
</table>

### O Canada!

O Canada!  
Our home and native land!  
True patriot love in all thy sons command.  
With glowing hearts we see thee rise,  
The True North strong and free!  
From far and wide,  
O Canada, we stand on guard for thee.  
God keep our land glorious and free!  
O Canada, we stand on guard for thee.  
O Canada, we stand on guard for thee.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 - 2:40 pm</td>
<td>Diagnostics &amp; Therapeutics</td>
<td>Salle de bal</td>
</tr>
<tr>
<td></td>
<td>Moderate: Dr. Dean Befus</td>
<td>AllerGen Diagnostic and Therapeutics Research Programme Co-Leader</td>
</tr>
<tr>
<td>1:00 - 1:20 pm</td>
<td><em>Role of mast cells and eosinophils in allergic inflammation and fibrosis of the lung</em></td>
<td>Dr. Kelly McNagny</td>
</tr>
<tr>
<td></td>
<td>AllerGen Investigator, University of British Columbia</td>
<td></td>
</tr>
<tr>
<td>1:20 - 1:40 pm</td>
<td><em>Stem cells as markers of allergic disease</em></td>
<td>Dr. Judah Denburg</td>
</tr>
<tr>
<td></td>
<td>AllerGen Investigator, McMaster University</td>
<td></td>
</tr>
<tr>
<td>1:40 - 2:00 pm</td>
<td><em>Intracellular Cytokine Production Biomarkers</em></td>
<td>Dr. Bruce Mazer</td>
</tr>
<tr>
<td></td>
<td>AllerGen Investigator, McGill University</td>
<td></td>
</tr>
<tr>
<td>2:00 - 2:20 pm</td>
<td><em>Perinatal stress and programming of allergic responses</em></td>
<td>Dr. Petra Arck</td>
</tr>
<tr>
<td></td>
<td>AllerGen Investigators, McMaster University</td>
<td>Dr. Paul Forsythe</td>
</tr>
<tr>
<td>2:20 - 2:40 pm</td>
<td><em>Socio-spatial investigations of stress, asthma and allergic disease</em></td>
<td>Dr. Anita Kozyrskyj</td>
</tr>
<tr>
<td></td>
<td>AllerGen Investigator, University of Alberta</td>
<td></td>
</tr>
<tr>
<td>2:40 - 3:00 pm</td>
<td>Break</td>
<td>Frontenac &amp; Petit</td>
</tr>
<tr>
<td>3:00 - 3:20 pm</td>
<td>Canadian Healthy Infant Longitudinal Development (CHILD) Study Update</td>
<td>Salle de bal</td>
</tr>
<tr>
<td></td>
<td>Moderate: Dr. Judah Denburg</td>
<td>Scientific Director &amp; CEO, AllerGen, NCE Inc.</td>
</tr>
<tr>
<td></td>
<td>Dr. Padmaja Subbarao</td>
<td>AllerGen Investigator, Deputy Director, CHILD Study and Ontario Site Leader,</td>
</tr>
<tr>
<td></td>
<td>The Hospital for Sick Children, Toronto</td>
<td></td>
</tr>
<tr>
<td>3:20 - 3:50 pm</td>
<td>Clinical Investigator Collaborative Update</td>
<td>Dr. Judah Denburg</td>
</tr>
<tr>
<td></td>
<td>Scientific Director &amp; CEO, AllerGen, NCE Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr. Paul O’Byrne</td>
<td>AllerGen Investigator, McMaster University</td>
</tr>
<tr>
<td></td>
<td>Dr. Gail Gauvreau</td>
<td>AllerGen Investigator, McMaster University</td>
</tr>
<tr>
<td></td>
<td>Dr. Scott Tebbutt</td>
<td>AllerGen Investigator, University of British Columbia</td>
</tr>
<tr>
<td>3:50 - 4:00 pm</td>
<td>Closing Remarks</td>
<td>Dr. Claude Roy</td>
</tr>
<tr>
<td></td>
<td>Gastroenterologist and Professor Emeritus, Hôpital Ste-Justine</td>
<td>AllerGen Board of Directors and Chair, 2010 Research Conference Planning Committee</td>
</tr>
</tbody>
</table>

**O Canada!**

O Canada!  
Terre de nos aïeux,  
Ton front est ceint de fleurons glorieux!  
Car ton bras sait porter l’épée,  
Il sait porter la croix!

Ton histoire est une épopée  
Des plus brillants exploits.  
Et ta valeur, de foi trempée,  
Protégera nos foyers et nos droits.  
Protégera nos foyers et nos droits.
Featured Speakers
Sunday, February 7, 2010

Dr. Suzanne Fortier, PhD, has served as President of the Natural Sciences and Engineering Research Council of Canada (NSERC) since January 2006. Before her appointment to this position, Dr. Fortier was a member of Queen’s University as Professor in both the Department of Chemistry and the School of Computing. She also served as Vice-Principal (Research) from 1995 to 2000 and Vice-Principal (Academic) from 2000 to 2005. Dr. Fortier is currently a member of the Ontario Task Force on Competitiveness, Productivity and Economic Progress, and the Board of Directors of the Canada Foundation for Innovation.

Mr. Jean-Claude Gavrel was appointed Associate Vice President of the Networks of Centres of Excellence Program in October 2007, having served as Program Director since 2000. Under his leadership, the program has doubled in size and launched several new initiatives, including the Centres of Excellence for Commercialization and Research (CECRs), the Business-led Networks and the Industrial R&D Internship program. Mr. Gavrel has a broad and intimate knowledge of R&D collaborations and partnerships gained over 25 years working with both private and public research organizations.

Dr. Michael S. Kramer, James McGill Professor in the Departments of Pediatrics and of Epidemiology and Biostatistics at McGill University Faculty of Medicine, and Scientific Director of the Institute of Human Development, Child, and Youth Health of the Canadian Institutes of Health Research. His systematic review of the evidence on the optimal duration of exclusive breastfeeding led directly to new infant feeding recommendations by WHO and the World Health Assembly. His current principal areas of research are the causes and prevention of preterm birth and intrauterine growth restriction, the determinants of fetal and infant mortality, and the long-term child health effects of breastfeeding.

Dr. Marc Ouellette is currently a Full Professor in the Faculty of Medicine at Laval University and a researcher at the Infectious Disease Research Centre of the Laval University Hospital Centre (CHUL). He holds a Canada Research Chair in Antimicrobial Resistance and a Burroughs Wellcome Fund Scholar Award in Molecular Parasitology. Dr. Ouellette studies antimicrobial resistance mechanisms in bacteria and in parasites. He devotes much of his research to the parasite Leishmania, which is transmitted to humans by the bite of certain insect species that are present in tropical regions. Leishmania is responsible for leishmaniasis, which causes disorders of the skin and internal organs.

Ms. Ainsley Chapman is the Director of the National Lung Health Framework, and has been involved in this strategic planning initiative since its inception in 2006. She has played many roles in the public health sector in the areas of health education, qualitative research, policy analysis, and strategic planning, in topic areas ranging from HIV/AIDS and sexual health to cardiovascular disease. She received a Masters degree in Sociology at Concordia University.

Dr. Claude C. Roy, MD, Professor Emeritus, University of Montreal, Gastroenterologist, Ste-Justine University Hospital, was born and educated in Quebec City, started his academic career at the University of Colorado Medical Centre and moved to Montreal in the 70s. He greatly contributed to the creation of pediatric gastroenterology as a subspecialty. As a clinician scientist, he has published more than 400 papers and book chapters. In 1990 he was appointed Officer of the Order of Canada.

Monday, February 8, 2010

Dr. Louis-Philippe Boulet, MD, is a respirologist at the Institut universitaire de cardiologie et de pneumologie de Québec (Quebec Heart & Lung Institute) and Professor of Medicine at Laval University, Quebec City, Canada. He currently holds a chair in Knowledge Transfer, Education and Prevention of Respiratory and Cardiovascular Health at Laval University. He is the Chair of the Canadian Thoracic Society (CTS) Respiratory Guidelines Committee and is an active member of many national and international medical societies and committees including the World Allergy Organisation (WAO), Global Alliance against Chronic Respiratory Diseases (GARD), and various CTS, American Thoracic Society and European Thoracic Societies Task Forces.
Dr. Catherine Tribouley, MD, has been working in the field of gene expression analysis and biomarkers identification for the last ten years. She is currently involved at Merck with the planning, design and analysis of genomic and genetic studies in the pre-clinical and clinical space for the identification of biomarkers and novel targets in respiratory indications. Prior to Merck, she has led teams and projects developing platforms for the identification of disease biomarkers in Oncology and novel target discovery at Incyte Genomics and Gene Logic. She started her career at Chiron Corporation, now part of Novartis, as a research scientist discovering and characterizing novel cytokines, their receptors and signal transduction pathways.

Dr. Allan B. Becker, MD, FRCP(C) is Professor and Head of the Section of Allergy and Clinical Immunology in the Department of Pediatrics and Child Health at the University of Manitoba and a consultant allergist at Children's Hospital of Winnipeg. Dr. Becker's primary research interest is the origins of allergy and asthma in early life. He is co-PI of “The Canadian Asthma Primary Prevention Study” and leads two CIHR teams in asthma research. He is co-PI of the Canadian Healthy Infant Longitudinal Development (CHILD) Study.

Dr. Ann E. Clarke, MD, MSc, FRCP(C) is a Professor in the Divisions of Clinical Immunology/Allergy and Clinical Epidemiology in the Department of Medicine, McGill University, Montreal, Quebec, Canada. Dr. Clarke received her Medical Degree at Memorial University of Newfoundland, Canada and completed a Residency in Internal Medicine and Fellowship in Clinical Immunology and Allergy at McGill University. She pursued a Post-Doctoral Fellowship at Stanford University, obtaining a Masters degree in Health Services Research. She is a Chercheur National of the Fonds de la Recherche en Santé du Québec and is receiving research support from the AllerGen Network of Centres of Excellence and the Canadian Institutes of Health Research. Dr. Clarke’s research focuses on the epidemiology, natural history, diagnosis, and management of food allergy.

Dr. Lisa Cicutto, PhD, APN, RN, is an Associate Professor with appointments the Faculties of Nursing and Medicine at the University of Toronto and in the College of Nursing, University of Colorado, Denver and the Colorado School of Public Health. She has participated in asthma and allergy research for the past 15 years with studies covering bench to community aspects. Since completing her doctorate, her research program has focused on optimizing the management of asthma and allergies focusing on patients, families, community settings, health care professionals, and health related policy.

Dr. Samuel Godefroy, PhD, is the Director General of the Food Directorate, in the Health Products and Food Branch, Health Canada. He joined Health Canada in 1998 as a research scientist, specializing in the development of analytical methods to detect contaminants in food. Samuel has led Health Canada’s Allergen Method Development program since late 2000. Before taking on Director General’s responsibilities, Samuel led the Bureau of Chemical Safety, part of Health Canada’s Food Directorate.

Ms. Laurie Harada, BA, BEd, Executive Director, Anaphylaxis Canada. As Executive Director and national spokesperson for Anaphylaxis Canada since 2003, Laurie is responsible for the organization’s national office. Her work extends to building partnerships with government, industry, healthcare professionals, researchers, and other allergy associations in Canada and overseas. One of Laurie’s two children (a teenager) has multiple food allergies.

Ms. Sara Shannon lost her daughter and only child, Sabrina Shannon to an anaphylactic reaction on September 30, 2003. Since her daughter's death, Sarah has become very involved in advocating for the rights of children at risk for anaphylaxis both in Canada and worldwide. She has been recognized for her work by various allergy groups across the country and by the food Allergy Initiative (FAI) in New York and was a driving force behind the enactment of Sabrina’s Law in Ontario.

Dr. Susan Elliott, PhD, is a medical geographer in the School of Geography and Earth Sciences at McMaster University as well as a Senior Research Fellow at the United Nations University Institute on Water, Environment and Health. She has published extensively in the area of psychosocial impacts of environmental exposure. In July 2010, she will take up the position as Dean of Applied Health Sciences at the University of Waterloo.
Dr. Susan Waserman, MD, obtained her MSc and medical degree from McGill University. She specialized in Internal Medicine, followed by subspecialty training in Allergy/Clinical Immunology, then completed a two-year fellowship at the Meakins Christie Laboratories at McGill University in Montreal. She is currently a Professor of Medicine, in the Division of Allergy/Clinical Immunology at McMaster University in Hamilton, where she has been since 1991. She was Training Program Director of the Allergy/ Clinical Immunology training program for 13 years. She is the Director of the Adverse Reactions Clinic at the Firestone Institute of Respiratory Health, St Joseph’s Hospital, Hamilton.

Dr. Anthony Levinson, MD, FRCP(C), is an Associate Professor at McMaster University, holds the John R. Evans Chair in Health Sciences Educational Research and Instructional Development, and is Director of e-Learning Innovation for the Michael G. DeGroote School of Medicine. He chairs the e-curriculum sub-group of the Council of Ontario Faculties of Medicine, is a member of the national e-learning group for the Association of Faculties of Medicine of Canada, and a member of the e-Learning Advisory Group for the Royal College. Dr. Levinson currently holds research funding and grants from several groups for the development and evaluation of e-Learning. His primary areas of expertise include technology-enabled knowledge translation and he is studying how best to capitalize on multi-media and new technologies to enhance health sciences education.

Dr. Judah Denburg, MD, FRCP(C) is Director and Chief of Service of Clinical Immunology and Allergy at Hamilton Health Sciences, McMaster Division. He is a Professor in the Department of Medicine, Faculty of Health Sciences having received his Professorship in 1988, and holds the William J. Walsh Professorship in General Internal Medicine. In addition to his other duties, Dr. Denburg is the Scientific Director and CEO of AllerGen NCE Inc., a Network of Centres of Excellence. Dr. Denburg is active as a physician, with one of the largest practices in allergy and immunology in Canada. Dr. Denburg’s primary research interest is the developmental biology of eosinophils, basophils and mast cells, and their regulation in allergic inflammation; his pioneering investigations on the systemic nature of allergy have had a profound impact on clinical and basic scientific investigations in the field. Dr. Denburg is also a recognized expert on autoimmune diseases such as systemic lupus erythematosus (SLE).

Dr. Sven-Erik Dahlén, MD, is one of the pioneers in the field of leukotrienes and asthma, which has contributed to the development of a new class of drugs, the anti-leukotrienes. He is the Director of the Center for Allergy Research at Karolinska Institutet. He is also the Director for Research of the European Respiratory Society (ERS) and is the PI of the European Network for Understanding Mechanisms in Severe Asthma (ENFUMOSA). He has over the years had many leadership appointments within KI and nationally, including advisor to the Swedish Public Health Institute and member of the Scientific Board of the National Heart and Lung Foundation. He has published about 250 papers and ten books.

Dr. Krishnamachari Srinivasanis, MD, currently the Vice Dean, St. John’s Research Institute and Professor, Department of Psychiatry, St. John’s Medical College, Bangalore, India. His research interests include studying autonomic nervous system function in children and adults with mood disorders, impact of antenatal and postnatal maternal stress and depression on child development and understanding the role of stress in chronic medical conditions.

Dr. Teresa To, PhD, is a Senior Scientist and Head of Child Health Evaluative Sciences, at the Hospital for Sick Children Research Institute. She is an Associate Professor in the Departments of Health Policy, Management & Evaluation, Paediatrics and the Dalla Lana School of Public Health at the University of Toronto, and an Adjunct Senior Scientist at the Institute for Clinical Evaluative Sciences in Toronto. Dr. To's research examines patterns of healthcare utilization, access to care and practice patterns for a variety of medical and surgical conditions, with a focus on developing longitudinal surveillance systems for chronic respiratory diseases.

Dr. Paul O’Byrne, MD, is currently the E.J. Moran Campbell Professor of Medicine, and Chair of the Department of Medicine at the Michael G. DeGroote School of Medicine, McMaster University. He is also the Executive Director of the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare. His research interests are on the mechanisms and treatment of asthma with particular reference to the role of environmental allergens and the mechanisms by which these cause airway inflammation.

Dr. Jean Marshall, PhD, received her PhD from the University of Manchester and completed postdoctoral training in the UK and at McMaster University where she obtained her first Faculty appointment. She is currently a Professor and Head of the Department of Microbiology and Immunology at Dalhousie University in Halifax where she leads a research group examining the role of mast cells in immune regulation and host defence.
Manel Jordana, MD, PhD, is Professor Pathology and Molecular Medicine, McMaster University, and Head, Respiratory Diseases and Allergy Division, Centre for Gene Therapeutics, Tier 1 Canada Research Chair in Immunobiology of Respiratory Diseases and Allergy. His laboratory is focused on understanding the origin and evolution of allergy and allergic diseases. His research activities are grouped into two main directions: allergic airway disease, particularly asthma, and food allergy, particularly peanut allergy.

Dr. Jeremy Scott, PhD, is an Assistant Professor in the Department of Medicine and the Dalla Lana School of Public Health at the University of Toronto and a Scientist of the Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. He completed his H.BSc, MSc, and PhD in Pharmacology and Toxicology at the University of Western Ontario. His research interests are related to understanding the mechanisms underlying occupational and environmental exposures and allergic airways diseases, and the effect of routes of sensitization and challenge on the response to food allergens. He is a member of the Steering Committee for CanGoFAR.

Dr. Ryan Allen has a PhD in environmental health from the University of Washington and is currently an assistant professor in the Dalla Lana School of Public Health and Department of Chemical Engineering at the University of Toronto. He currently co-leads AllerGen’s Gene-Environment Interactions Programme and he leads the environmental exposure assessment component of a national birth cohort (CHILD Study) examining the influences of environmental factors on children’s health.

Dr. Chris Carlsten, MD, MPH, is an assistant professor and Chair in Occupational and Environmental Lung Disease at the University of British Columbia. His clinical and research interests center on occupational airways disease, including the effects of diesel exhaust and other particulate matter on asthma induction and exacerbation.

Dr. Tim Takaro, MD, is a physician-scientist and Associate Dean for Research at Simon Fraser University’s Faculty of Health Sciences. His research interests are in environmental and occupational lung disease and the human health effects of climate change with collaborations in the US and Canada, Cuba, Mongolia, Iraq, Bangladesh and Ecuador.

Dr. Denise Daley, PhD, an Assistant Professor in the Department of Medicine at the University of British Columbia, and currently holds a Canada Research Chair in Genetic Epidemiology of Complex Diseases and Michael Smith Foundation Career Investigator Award. Dr. Daley is a Principal Investigator at the James Hogg iCAPTURE Centre in Vancouver and studies complex diseases such as asthma, cancer and heart disease, with a focus on gene–gene and gene-environment interactions. In particular, she has focused on why some children get asthma and others do not. Dr. Daley is currently investigating genes that may predispose children to developing asthma, and how a combination of genetic variations can interact with gender and the environment to produce the condition.

Dr. Andrew Sandford, PhD, is an Associate Professor in the Department of Medicine, University of British Columbia. His research is focused on the investigation of the genetic basis of obstructive lung disease.
Dr. Catherine Laprise, PhD, is currently the holder of the Canada Research Chair on genetic determinants of asthma, co-director of the Gépomic laboratory and professor at UQAC, Université Laval and Université de Sherbrooke. Catherine Laprise is an investigator in the AllerGen Programme A, Gene-Environment Interactions and she is responsible for the Inflammation and Remodeling Strategic Group of the Respiratory Health Network of the FRSQ. Her laboratory manages one of the most important characterized familial collection of DNA for asthma and her research team works at identifying asthma and asthma-related susceptibility and protection genes while focusing on gene-gene and gene-environment interactions. She also studies the transcriptome of this pathology using cellular and bronchial tissue models.

Dr. Dean Befus, PhD, is the AstraZeneca Canada Inc., Chair in Asthma Research, Director of the Alberta Asthma Centre, Director of the Magnetic Resonance Diagnostic Centre (MRDC), and Professor of Medicine. He is co-leader, Diagnostics and Therapeutics Programme, AllerGen NCE Inc. In 1996 he co-founded Salpep Biotechnology Inc., now AIM Therapeutics Inc.

Dr. Kelly McNagny, PhD, is a Professor of Medical Genetics at The Biomedical Research Centre, UBC. His work has focused on transcriptional control of hematopoietic stem cell maturation and cell fate and also on the cell surface proteins stem cells use to communicate with their environment. His group has shown that the CD34 family of sialomucins is essential for a number of developmentally important processes and disease progression. These include such diverse processes as: 1) gut and kidney formation, regulation of vascular permeability, allergic and mucosal inflammatory responses, clearing infections, tumor progression, and stem cell homing and migration. Dr. McNagny is a Michael Smith Foundation for Health Research Senior Scholarship, and an active member of the Stem Cell, AllerGen, and Stroke Network Centres of Excellence.

Dr. Bruce Mazer, MD, is an Associate Professor of Pediatrics at McGill University and Division Head of Allergy and Immunology at the Montreal Children's Hospital. He is a member of the McGill University Heath Centre Research Institute, and his lab is based at the Meakins Christie Laboratories. Dr. Mazer's work is on the regulation of B-lymphocyte growth and survival in allergic airway tissues and the role of innate immune signals on IgE regulation.

Dr. Petra Arck, MD, obtained her medical training and her medical doctoral thesis at Tuebingen University in Germany in 1993. She completed research training in immunology at McMaster University and the University of Toronto before returning to Germany in 1997 to finish her medical training in Gynecology. She has become a full faculty member of the Charité, University Medicine Berlin in 2006 and joined the Department of Medicine at McMaster University in 2008 as a Canada Research Chair in Neuroimmunology.

Dr. Paul Forsythe, obtained his PhD from Queen's University Belfast, UK, before coming to Canada as a post-doctoral fellow at the University of Alberta. He continued his post-doctoral training at the Brain-Body Institute, McMaster University before joining the Faculty of Medicine as an assistant Professor in 2008. Dr. Forsythe's research interests include understanding how the nervous system controls inflammatory responses and the role of commensal bacteria in modulating the immune system, particularly in relation to allergic diseases and asthma.

Dr. Anita Kozyrskyj, PhD, is Research Chair, Maternal-Child Health and the Environment, and Associate Professor in the Department of Pediatrics, Faculty of Medicine and Dentistry at the University of Alberta. She is an epidemiologist-health services researcher, with expertise in population-based studies using provincial prescription and health care databases. Her research spans several areas, from the early life origins (e.g., antibiotic use, maternal distress) of childhood asthma to policy research on pharmaceuticals. She has held several CIHR grants which created the Study of Asthma, Genes and the Environment (SAGE), a novel birth cohort of 14,000 Manitoba children established from health care database records, with data linkages to clinical assessments, home environment exposures and biologic samples.

Dr. Padmaja Subbarao MD, MSc, FRCP(C) is a Clinician-Scientist and pediatric respirologist in the Division of Respiratory Medicine at the Hospital for Sick Children and Deputy Director of the CHILD Study. Her primary research interest is in the early determinants and development of asthma and she has set up the first infant pulmonary function laboratory in Canada performing a combination of lung function and airway assessment tests. She has received funding from AllerGen NCE, CIHR and the NIH to study asthma in infants and older children.
AllerGen NCE Inc. is dedicated to improving the quality of life for people suffering from allergic and related immune disease.

**AllerGen’s Mission:** To catalyze and support discovery, development, networking, capacity building, commercialization and knowledge translation that contribute to reducing the morbidity, mortality and socio-economic burden of allergic and related immune diseases.

**AllerGen’s Vision:** To create an enduring network of allergy and immune disease experts whose discovery and development efforts contribute to reducing the impact of allergic and related immune diseases nationally and globally.

AllerGen’s Strategic Goals are to:

- Catalyze and support innovative research that contributes to the discovery of the causes of, and ways to prevent, control or eliminate allergic and related immune diseases.
- Catalyze and facilitate the development of new research platforms, tools, processes, products and services arising from discoveries, and promote their commercialization, their use and their influence on public policy.
- Develop and maintain networking and partnership arrangements that enable knowledge and technology exchange and exploitation (KTEE) and reposition Canada at the forefront of innovation.
- Create new opportunities for the training of highly qualified personnel (HQP) in allergy research, patient care, innovation and the health system, and advance professional and lay knowledge about allergic and related immune diseases.
- Provide responsible, cost effective and accountable management, administration and support to all aspects of AllerGen’s activities.

AllerGen research priorities include three research foci of strategic importance to the generation of new knowledge with potential for social and economic impact in the area of allergic and related immune disease.

### Strategic Research Programme Foci:

1. **Programme A - Gene-Environment Interactions**
   - Strategic Focus: Genetics and gene-environment interactions in allergy and asthma

2. **Programme B – Diagnostics and Therapeutics**
   - Strategic Focus: Biomarkers, immune monitoring and drug development/discovery

3. **Programme C – Public Health, Ethics, Policy and Society**
   - Strategic Focus: Allergic disease management and surveillance

In addition, four cross-programmatic, multidisciplinary research thrusts fostered by AllerGen since 2005 are continuing research investment priorities for 2009-2012:

#### Established Cross-programmatic Teams

4. The Canadian Healthy Infant Longitudinal Development (CHILD) Study
5. Food Allergy and Anaphylaxis

#### Emerging Cross-programmatic Teams

6. Mind-Body Interactions and Allergic Disease
7. Work-related Allergy and Asthma
At McMaster, we know complex issues require integrated solutions. Digging deep is second nature to us. Our innovative and multi-disciplinary approach to research has earned us international acclaim. But more than that, it’s helped to save lives and contribute to the nation’s social and economic well-being. It is indeed fitting that McMaster University is home to AllerGen NCE Inc., a dynamic centre of excellence that shares our philosophy and approach to research.

The heights we reach depend on the depth of our roots

At McMaster, we know complex issues require integrated solutions. Digging deep is second nature to us. Our innovative and multi-disciplinary approach to research has earned us international acclaim. But more than that, it’s helped to save lives and contribute to the nation’s social and economic well-being.

It’s the simple things in life that make a difference. Advances in research are helping simplify asthma therapy for children and parents. Scientists at the Merck Frosst Centre for Therapeutic Research have made important discoveries in the field of respiratory diseases such as asthma. As long as there is disease and suffering, we will continue our search.

Mark your calendars!

INNOVATION from cell to society
Sixth Annual Research Conference
February 7 - 10, 2011 • Vancouver

The 98,000 employees of Novartis based in 140 countries worldwide share a vision of a better today and tomorrow for patients – a vision that drives its growth and success. The greatest job satisfaction for its employees is the knowledge that they improve the quality of life for patients with increasing precision and efficiency through breakthrough science and innovation.
A special thank you to our sponsors for their generous support of Innovation from Cell to Society⁵

Conference Sponsors

Canadian Allergy, Asthma and Immunology Foundation

Canadian Society of Allergy and Clinical Immunology

Media Sponsor

Longwoods.com
GlaxoSmithKline

Your Partner in Respiratory Care
is pleased to support AllerGen’s
Fifth Annual Research Conference

GlaxoSmithKline (GSK) is a research-based pharmaceutical company devoted
to discovering and developing new and innovative medicines, vaccines and
healthcare products for Canadians and people around the world.

www.gsk.ca

Do more, feel better, live longer